Alzheimer's Trial: Lessons From a Failed Drug
— What the pragmatic trial of minocycline can teach us
Minocycline (Minocin), an anti-inflammatory tetracycline that crosses the blood-brain barrier and inhibits proinflammatory microglia, did not improve cognitive or functional performance in people with mild Alzheimer's disease over 2 years, the MADE trial showed.
There was no significant difference in either standardized Mini-Mental State Examination (MMSE) or Bristol Activities of Daily Living Scale (BADLS) scores among participants who took minocycline daily for 24 months or placebo, reported Robert Howard, MD, MRCPsych, of University College London in England, and coauthors, in JAMA Neurology.
No comments:
Post a Comment